Welcome to Trends-in-Medicine, offering independent, cutting-edge articles and information on drugs and devices in development. Our subscribers have access to news and analysis on the latest data, regulatory issues, and trends of interest to the healthcare community.

FDA Oncology Drugs Advisory Committee (ODAC) Update

This is a must read for anyone interested in ODAC because changes are coming: In-person meetings will resume, less emphass on industry “outside experts,” a new style for briefing documents, encouragement for more “pragmatic” trials. Two things that won't change: panels will continue to vote, and drug prices will continue to be left out of discussions.

Alzheimer's Update

The data on Eisai and Biogen’s Leqembi (lecanemab) was the highlight of the Clinical Trials on Alzheimer's Disease (CTAD) meeting in Boston. Here we dive into the data.

Retina Update

Three new drugs for geographic atrophy had mixed news at ASRS: (10 A safety issue reported with Apellis Pharmaceuticals’ Syfovre (pegcetacoplan), a complement C3 inhibitor, (2) Efficacy questions about Astellas/Iveric Bio’s Izervay (avacincaptad pegol), a complement C5 inhibitor, and (3) an efficacy miss for Annexon Biosciences’ ANX-007, A complement C1q inhibitor. And there was positive data on sevral other drugs.

AI Perspectives

Where is artificial intelligence going in healthcare? Here is a Perpective from one of our technology-savvy reporters